FDA Approves LITFULO — Pfizer Laboratories Div Pfizer Inc

Pfizer has announced the FDA approval of the oral drug Ritlecitinib Tosylate (LITFULO) for the treatment of alopecia areata, marking the pharma giant's latest expansion into the complex hair loss market as Amgen also advances its own candidate in this space. This approval enhances Pfizer’s dermatology portfolio and offers a critical new therapeutic option for patients facing chronic hair loss.